Keywords: Shire, VPRIV, Cerezyme, Gaucher's disease

UK’s Shire demonstrates safety of switching to its VPRIV from Cerezyme

Article | 26 March 2010

Print This

UK drugmaker Shire has presented new data showing that switching to its Gaucher disease drug VPRIV (velaglucerase alfa for injection)) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in